DK3638251T3 - BISPHOSPHOCINE GEL FORMULATIONS AND USES THEREOF - Google Patents
BISPHOSPHOCINE GEL FORMULATIONS AND USES THEREOF Download PDFInfo
- Publication number
- DK3638251T3 DK3638251T3 DK18816615.1T DK18816615T DK3638251T3 DK 3638251 T3 DK3638251 T3 DK 3638251T3 DK 18816615 T DK18816615 T DK 18816615T DK 3638251 T3 DK3638251 T3 DK 3638251T3
- Authority
- DK
- Denmark
- Prior art keywords
- bisphosphocine
- gel formulations
- formulations
- gel
- bisphosphocine gel
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762518262P | 2017-06-12 | 2017-06-12 | |
PCT/US2018/037151 WO2018231863A1 (en) | 2017-06-12 | 2018-06-12 | Bisphosphocin gel formulations and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3638251T3 true DK3638251T3 (en) | 2024-05-13 |
Family
ID=64562861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18816615.1T DK3638251T3 (en) | 2017-06-12 | 2018-06-12 | BISPHOSPHOCINE GEL FORMULATIONS AND USES THEREOF |
Country Status (14)
Country | Link |
---|---|
US (4) | US11096954B2 (en) |
EP (2) | EP4241769A3 (en) |
JP (2) | JP7148994B2 (en) |
KR (2) | KR20200014904A (en) |
CN (1) | CN110753549A (en) |
AU (3) | AU2018282905B2 (en) |
BR (2) | BR122021011439B1 (en) |
CA (1) | CA3066722A1 (en) |
DK (1) | DK3638251T3 (en) |
ES (1) | ES2981923T3 (en) |
FI (1) | FI3638251T3 (en) |
MX (1) | MX2019014772A (en) |
PT (1) | PT3638251T (en) |
WO (1) | WO2018231863A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5887044B2 (en) | 2005-04-15 | 2016-03-16 | クラルス セラピューティクス, インコーポレーテッドClarus Therapeutic, Inc. | Hydrophobic drug delivery system and composition thereof |
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
US11795192B2 (en) | 2017-03-10 | 2023-10-24 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
US11377468B2 (en) | 2017-03-10 | 2022-07-05 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
EP4272832A3 (en) * | 2017-03-10 | 2023-11-22 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
US12030908B2 (en) | 2017-03-10 | 2024-07-09 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
BR122021011439B1 (en) | 2017-06-12 | 2022-03-29 | Lakewood Amedex, Inc | Bisphosphocine gel formulation and uses |
CN112839662A (en) * | 2018-10-17 | 2021-05-25 | 莱克伍德阿美达克斯股份有限公司 | Methods and compositions for treating oral mucositis |
US20230092578A1 (en) * | 2021-07-22 | 2023-03-23 | Lakewood Amedex, Inc. | Methods for preparing bisphosphocins |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105782A (en) | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
SE8004580L (en) * | 1980-06-19 | 1981-12-20 | Draco Ab | PHARMACEUTICAL PREPARATION |
KR830005852A (en) * | 1980-07-18 | 1983-09-14 | 미첼 페터 잭슨 | Preparation of topical treatments suitable for the treatment of viral infections on skin and mucous membranes |
US4421769A (en) * | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
DE3542516A1 (en) | 1985-12-02 | 1987-06-04 | Henkel Kgaa | DISINFECTANT |
US5266310A (en) | 1987-09-17 | 1993-11-30 | Boehringer Ingelheim International Gmbh | Stabilization of therapeutically active proteins in pharmaceutical preparations |
DE3731255A1 (en) * | 1987-09-17 | 1989-04-06 | Boehringer Ingelheim Int | Stabilization of therapeutically active proteins in pharmaceutical preparations |
US5153230A (en) | 1989-10-06 | 1992-10-06 | Perfective Cosmetics, Inc. | Topical skin cream composition |
US5167950A (en) * | 1991-03-28 | 1992-12-01 | S. C. Johnson & Son | High alcohol content aerosol antimicrobial mousse |
US5208015A (en) * | 1991-07-23 | 1993-05-04 | Bristol-Myers Squibb Company | Topical anti-fungal agents having anti-inflammatory activity |
DE4333385C2 (en) | 1993-09-30 | 1997-01-30 | Friedrich A Spruegel | Surface disinfectants and cleaning agents |
CZ267396A3 (en) * | 1994-03-11 | 1997-03-12 | Procter & Gamble | HYDROLYTIC STABLE COSMETIC, PREPARATION WITH LOW pH VALUE CONTAINING ACID ACTIVE SUBSTANCES |
FR2718022B1 (en) | 1994-04-01 | 1996-04-26 | Roussel Uclaf | Cosmetic or dermatological compositions and their preparation. |
FR2722102B1 (en) * | 1994-07-11 | 1996-08-23 | Cird Galderma | USE OF DEFORMABLE HOLLOW PARTICLES IN A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING FAT MATERIALS |
US5843998A (en) | 1997-06-30 | 1998-12-01 | Song; Jin | Skin blemish treatment |
US6627215B1 (en) | 1998-12-30 | 2003-09-30 | Oligos Etc. Inc. | Devices for improved wound management |
US7868162B2 (en) * | 1998-12-30 | 2011-01-11 | Lakewood-Amedex, Inc. | Antimicrobial and antiviral compounds and methods for their use |
US20020032164A1 (en) | 1998-12-30 | 2002-03-14 | Dale Roderic M. K. | Antimicrobial compounds and methods for their use |
US6211349B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc., Inc. | Protonated/acidified nucleic acids and methods of use |
US6211162B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc. Inc. | Pulmonary delivery of protonated/acidified nucleic acids |
US6156294A (en) | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
AU2002337862A1 (en) * | 2001-10-18 | 2003-04-28 | Ilex Products, Inc. | Methods of treating skin with diphosphonate derivatives |
WO2004093886A1 (en) * | 2003-04-24 | 2004-11-04 | Galderma S.A. | Topical formulation of ivermectin for the treatment of dermatological conditions |
CN1687100A (en) * | 2005-04-05 | 2005-10-26 | 奥林格斯技术有限公司 | Modification nucleotide and its use |
EP2149375A1 (en) | 2008-07-28 | 2010-02-03 | Despharma Kft. | Compositions for the treatment of dermatological diseases, and uses thereof |
JP5205549B2 (en) | 2009-04-13 | 2013-06-05 | スラー サブラマニアン ヴァナンガムディ | Medicinal fusidic acid cream produced using sodium fusidate and incorporating a biopolymer, and method for producing the same |
WO2015075406A1 (en) | 2013-11-19 | 2015-05-28 | Lipopeptide Ab | New treatment of chronic ulcers |
FR3041540B1 (en) | 2015-09-29 | 2018-10-26 | Galderma Research & Development | SELF-MOUSING CLEANING COMPOSITION FOR RINSING, CONTAINING IVERMECTIN. |
BR122021011439B1 (en) | 2017-06-12 | 2022-03-29 | Lakewood Amedex, Inc | Bisphosphocine gel formulation and uses |
-
2018
- 2018-06-12 BR BR122021011439-0A patent/BR122021011439B1/en active IP Right Grant
- 2018-06-12 BR BR112019026073-0A patent/BR112019026073B1/en active IP Right Grant
- 2018-06-12 EP EP23156658.9A patent/EP4241769A3/en active Pending
- 2018-06-12 MX MX2019014772A patent/MX2019014772A/en unknown
- 2018-06-12 US US16/006,660 patent/US11096954B2/en active Active
- 2018-06-12 PT PT188166151T patent/PT3638251T/en unknown
- 2018-06-12 ES ES18816615T patent/ES2981923T3/en active Active
- 2018-06-12 JP JP2019567981A patent/JP7148994B2/en active Active
- 2018-06-12 DK DK18816615.1T patent/DK3638251T3/en active
- 2018-06-12 WO PCT/US2018/037151 patent/WO2018231863A1/en active Application Filing
- 2018-06-12 AU AU2018282905A patent/AU2018282905B2/en not_active Ceased
- 2018-06-12 EP EP18816615.1A patent/EP3638251B1/en active Active
- 2018-06-12 CN CN201880038759.5A patent/CN110753549A/en active Pending
- 2018-06-12 KR KR1020207000424A patent/KR20200014904A/en active IP Right Grant
- 2018-06-12 KR KR1020237004991A patent/KR20230031370A/en not_active Application Discontinuation
- 2018-06-12 CA CA3066722A patent/CA3066722A1/en active Pending
- 2018-06-12 FI FIEP18816615.1T patent/FI3638251T3/en active
-
2020
- 2020-07-30 US US16/943,939 patent/US20200360415A1/en not_active Abandoned
-
2021
- 2021-08-09 US US17/396,989 patent/US12156883B2/en active Active
-
2022
- 2022-09-02 AU AU2022224829A patent/AU2022224829B2/en active Active
- 2022-09-15 JP JP2022147051A patent/JP7470449B2/en active Active
- 2022-12-16 US US18/083,378 patent/US20230125677A1/en not_active Abandoned
-
2024
- 2024-04-05 AU AU2024202211A patent/AU2024202211A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3638251A4 (en) | 2021-03-10 |
JP2022183154A (en) | 2022-12-08 |
EP4241769A3 (en) | 2023-11-08 |
US20210361689A1 (en) | 2021-11-25 |
AU2018282905A1 (en) | 2019-12-19 |
US20180353529A1 (en) | 2018-12-13 |
JP2020523322A (en) | 2020-08-06 |
US11096954B2 (en) | 2021-08-24 |
CN110753549A (en) | 2020-02-04 |
WO2018231863A1 (en) | 2018-12-20 |
US20200360415A1 (en) | 2020-11-19 |
EP4241769A2 (en) | 2023-09-13 |
JP7148994B2 (en) | 2022-10-06 |
AU2024202211A1 (en) | 2024-05-02 |
MX2019014772A (en) | 2020-02-07 |
CA3066722A1 (en) | 2018-12-20 |
EP3638251B1 (en) | 2024-03-06 |
EP3638251A1 (en) | 2020-04-22 |
US20230125677A1 (en) | 2023-04-27 |
BR112019026073B1 (en) | 2021-11-03 |
ES2981923T3 (en) | 2024-10-11 |
AU2022224829B2 (en) | 2024-12-05 |
FI3638251T3 (en) | 2024-04-29 |
KR20230031370A (en) | 2023-03-07 |
US12156883B2 (en) | 2024-12-03 |
BR112019026073A2 (en) | 2020-06-30 |
KR20200014904A (en) | 2020-02-11 |
AU2018282905B2 (en) | 2022-06-02 |
JP7470449B2 (en) | 2024-04-18 |
AU2022224829A1 (en) | 2022-09-29 |
PT3638251T (en) | 2024-05-22 |
BR122021011439B1 (en) | 2022-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3784283T3 (en) | CANNABIDIO PREPARATIONS AND USES THEREOF | |
DK3638251T3 (en) | BISPHOSPHOCINE GEL FORMULATIONS AND USES THEREOF | |
DK3478811T3 (en) | Cleaning compositions and uses thereof | |
DK3658557T3 (en) | TYK2 INHIBITORS AND USES THEREOF | |
DK3448386T3 (en) | ISOQUINOLIN-3-YLCARBOXAMIDES AND MANUFACTURE AND USE THEREOF | |
DK3607069T3 (en) | Products and compositions | |
DK3610005T3 (en) | PEPTIDLIGASE AND ITS USE | |
DK3485010T3 (en) | BACILLUS CIBI DNASE VARIANTS AND USES THEREOF | |
DK3668512T3 (en) | PYRUVACKINASE MODULATORS AND USES THEREOF | |
DK3452463T3 (en) | AMID-SUBSTITUTED PYRIDINYLTRIAZOLE DERIVATIVES AND USES THEREOF | |
DK3580561T3 (en) | HLA-BASED METHODS, COMPOSITIONS AND USES THEREOF | |
DK3357513T3 (en) | PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
DK3655401T3 (en) | TLR7/8 ANTAGONISTS AND USES THEREOF | |
DK3557998T3 (en) | COMPOSITIONS, COMPOSITIONS AND METHODS OF USE | |
DK3430129T5 (en) | COLONY-FORMING MEDIUM AND USE THEREOF | |
DK3423076T3 (en) | TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF | |
DK3536698T3 (en) | LANOSTEROL PRODUCT COMPOUND AND USE THEREOF | |
DK3621694T5 (en) | LRRC33 INHIBITORS AND USES THEREOF | |
DK3692009T3 (en) | BIOCEMENTATION PROCEDURE AND SYSTEM | |
DK3612579T3 (en) | PULTRUDATE, MANUFACTURE AND USE thereof | |
DK3420039T3 (en) | PRINTING FORMULATIONS AND METHODS | |
DK3743106T3 (en) | INFLUENZAVIRUS VACCINES AND USES THEREOF | |
DK3615502T3 (en) | THERAPEUTIC COMPOUNDS AND METHODS | |
EP3758712A4 (en) | CPG-AMPHIPHILES AND USES THEREOF | |
DK3321279T3 (en) | EXENATID MODIFICANT AND USE THEREOF |